ArticleDiabetes & metabolism2025
Diabetes prevalence, awareness, and control in the United States, 2017-2023.
Article in Diabetes & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diabetic retinopathy treatment cascade and care continuum in the USA: a systematic review.BMJ open · 2026Pooled it
- Mobile Health Unit Outreach to Socially Disadvantaged Urban Communities Detects Uncontrolled Cardiometabolic Risk Factors.Journal of the American Heart Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionWe compared diabetes prevalence, awareness, and control pre versus post the Covid-19 pandemic.
methodsThis was a cross-sectional analysis of the U.S. National Health and Nutrition Examination Surveys pre (2017-2020) and post (2021-2023) the pandemic. We included all non-pregnant adults (aged ≥ 20 years) who had undergone biomedical testing. Diagnosed and undiagnosed diabetes was defined as self-reported diabetes and no self-reported diabetes with HbA1c >6.5 % or fasting plasma glucose ≥126 mg/dL, respectively. Among diagnosed diabetes, we estimated proportions achieving glycemic (HbA1c < 7.0 %), blood pressure (< 130/80 mmHg), and cholesterol control (non-high-density lipoprotein < 130mg/dl), and use of blood pressure and lipid lowering medications.
resultsThe prevalence of total diabetes, diagnosed diabetes, undiagnosed diabetes, and proportion of diabetes that was undiagnosed remained stable between pre and post pandemic periods: from 16.2 % [95 %CI: 14.3-18.1] to 15.8 % [13.7-17.9], from 11.7 % [10.1-13.2] to 11.3 % [9.4-13.2], from 4.6 % [3.8-5.3]) to 4.5 % [3.4-5.6]), and from 28.1 % [24.3-31.8] to 28.4 % [21.9-35.0], respectively. Among those with diagnosed diabetes, glycemia, blood pressure, lipid control, and use of blood pressure or lipid medication did not significantly change.
conclusionsBetween 2017-2020 and 2021-2023, there were no significant changes in diabetes prevalence, awareness, and control in the U.S. POPULATION:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.